VisionX Medical Secures Over RMB 100 Million in Pre-B Round Financing Led by Sanzheng Health Investment and Honghui Capital

VCBeat (WeChat ID: vcbeat) has learned that Vision Xlab (referred to as “Vision Xlab”), a R&D and manufacturing enterprise dedicated to providing comprehensive innovative solutions for medical devices in the field of optometry and ophthalmology, recently completedPre-B Financing Round Exceeding 100 Million YuanThis round of financing was led by Sanzheng Health Investment and Honghui Capital, with existing shareholders including Sequoia Capital China, Sherpa Investments, Fosun RZ Capital, Sinopharm Capital, and Yuansheng Venture Capital participating in the follow-on investment.

Vision Xlab's Optometry Solutions,Covering myopia prevention and control in adolescents, vision correction and ocular surface disease treatment in adults, a full range of contact lens care products, and optometric examination equipment, among others.Among the various medical devices it is currently developing and manufacturing, including scleral lens products, are the first of their kind launched in China, filling a gap in the industry. Currently, pre-market clinical trials for Vision Xlab’s products are being sequentially conducted under the leadership of several well-known large eye hospitals in China, such as Wenzhou Eye Hospital.

This round of financing will further support Vision Xlab in accelerating and optimizing its strategic layout across the entire eye care and optometry industry, attracting top-tier global talent, expediting the R&D, regulatory registration, and commercialization of its multiple ophthalmic and optometric medical devices, while further expanding its product development pipeline.

In fact, this round of financing isVision Xlab's Series A FundingIn less than half a year.Li Xiaowei, founder of Vision Xlab, stated“The team’s strong execution capabilities, coupled with a diversified and comprehensive pipeline layout, provide ample room for growth potential.”Founding Partner Fu Xiaoyang believes“Vision Xlab’s rapid growth demonstrates the strength of its team and the company’s potential in technological R&D. It also reinforces Vision Xlab’s confidence in continuously incubating and creating value in the field of innovative medical devices. The successful financing round and the addition of new shareholders have injected momentum into the company’s next phase of development.”

Sheng Li, Partner at Sanzheng Health Investment, the lead investor in this round, stated“Ophthalmology is a key sector that Sanzheng Health Investment focuses on and strategically invests in. Vision Xlab boasts an industry-leading professional team, and with its strong execution capabilities and global perspective, it is committed to providing high-quality ophthalmic products to patients. We highly recognize Vision Xlab’s founding team and corporate culture, and we are delighted to participate in this round of financing. We look forward to working hand in hand with Vision Xlab in the future, helping it become a leading enterprise in China's ophthalmology industry.”

Jiang Yanye, spokesperson for Honghui Capital, stated“The scale of China’s ophthalmic healthcare market and its clinical demands are growing significantly, with a sharp rise in patient needs for optometry and vision care. As an emerging player in the field of ophthalmic devices, Vision Xlab has established a diverse product portfolio in recent years. Through this collaboration with a prestigious investment institution, we aim to support the Vision Xlab team in further advancing the development of optometric and ophthalmic medical devices.”

Cao Yibo, Managing Director of Sequoia Capital China Fund, who participated in this round of continuous co-investment, stated“Sequoia China has participated in every round of financing for Vision Xlab since its Series A. We have observed that the company has rapidly established a comprehensive portfolio addressing the major unmet needs in the field of ophthalmic devices and consumables. Sequoia China will continue to support the company’s organic and inorganic growth, drive the commercialization of its products, and strive to achieve a win-win outcome of business expansion and improved patient outcomes.”

Deng Xuan, Investment Director at Sherpa Capital, the lead investor in the angel round, also stated“Since the angel investment round, we have witnessed Vision Xlab’s steady growth into a leading Chinese ophthalmic device platform. Throughout this journey, the team has demonstrated exceptional learning agility, execution capability, and business innovation. Looking ahead, Sherpa Capital will continue to fully support Vision Xlab’s expansion and development, enabling the continuous launch of innovative products that benefit a broad population of patients with eye diseases.”